Global challenges Revision Notes

Common Human Infection: Measles

Measles is a highly contagious viral disease. It is spread through airborne droplets produced when an infected person coughs or sneezes. Key symptoms include a high fever and a characteristic red-brown skin rash that starts on the face and spreads downwards. Measles can lead to serious complications such as pneumonia, brain inflammation (encephalitis), and in severe cases, death. Vaccination with the MMR (Measles, Mumps, Rubella) vaccine is the most effective way to prevent measles, offering long-term immunity.

Common Plant Disease: Tobacco Mosaic Virus (TMV)

Tobacco mosaic virus (TMV) is a widespread plant pathogen that affects many species, including tobacco, tomatoes, and peppers. It is transmitted primarily through contact between infected and healthy plants, often by contaminated tools or hands. Symptoms include a distinctive 'mosaic' pattern of discoloration on leaves, stunted growth, and curled or distorted leaves. TMV reduces the plant's ability to photosynthesise effectively, leading to decreased crop yields. There is no chemical cure for TMV; management relies on sanitation, removal of infected plants, and using resistant plant varieties.

Sexually Transmitted Infections (STIs)

Sexually transmitted infections (STIs) are passed from one person to another through sexual contact. Examples include chlamydia, gonorrhoea, syphilis, and HIV/AIDS. These infections can have a range of symptoms, from mild to severe, and some may be asymptomatic for long periods. Untreated STIs can lead to serious health problems, including infertility, chronic pain, and an increased risk of other infections. Prevention includes practicing safe sex (e.g., using condoms), regular testing, and limiting the number of sexual partners.

HIV/AIDS: A Specific STI

HIV (Human Immunodeficiency Virus) is a virus that targets and destroys immune cells, specifically white blood cells called T-helper cells. This progressively weakens the body's immune system, making it less able to fight off infections and diseases. HIV is transmitted through the exchange of specific bodily fluids, including blood, semen, vaginal fluids, and breast milk, typically via unprotected sexual contact, sharing needles, or from mother to child during birth or breastfeeding. If left untreated, HIV can advance to AIDS (Acquired Immunodeficiency Syndrome), which is the final, life-threatening stage of HIV infection. While there is no cure, antiretroviral therapy (ART) can manage HIV, allowing individuals to live long and healthy lives.

Types of Disease Interactions

Diseases can interact in several ways, often making an individual more vulnerable to other conditions or worsening existing ones. These interactions primarily fall into categories like infectious diseases impacting non-communicable diseases (NCDs), NCDs increasing susceptibility to infections, and common risk factors contributing to multiple disease types. Understanding these links is vital for effective health management and prevention strategies across populations, enabling better targeted interventions and public health campaigns.

Infectious Diseases and NCDs

Some infectious agents can directly cause or contribute to the development of non-communicable diseases. A classic example is the Human Papillomavirus (HPV), which can lead to cervical cancer, a major NCD. Similarly, chronic hepatitis B and C infections are significant risk factors for liver cancer. These interactions highlight the importance of vaccination programs and early detection/treatment of infections to reduce the burden of associated NCDs, representing a direct pathogenic link between the two categories of diseases. Another example is Helicobacter pylori, a bacterium that can cause stomach ulcers and is also linked to an increased risk of stomach cancer.

NCDs Affecting Susceptibility to Infections

Non-communicable diseases can weaken the body's immune system or create conditions that make individuals more prone to infectious diseases, and often lead to more severe outcomes. For instance, people with diabetes mellitus are known to have impaired immune function, making them more susceptible to bacterial and fungal infections, such as urinary tract infections, pneumonia, and foot infections. Cardiovascular diseases can also make individuals more vulnerable to complications from infections like influenza. Asthma can increase the risk of respiratory infections. This bidirectional relationship means effectively managing NCDs can indirectly strengthen resistance against communicable diseases.

Common Risk Factors and Amplifying Effects

Many risk factors are not specific to a single disease type but contribute to the development or progression of several. For example, smoking is a well-established risk factor for various NCDs, including lung cancer, heart disease, and chronic obstructive pulmonary disease (COPD). It also weakens the immune system, increasing susceptibility to respiratory infections like bronchitis and pneumonia. Obesity is another significant risk factor for NCDs like type 2 diabetes and heart disease, and it can also complicate the course of infectious diseases. Poor nutrition, lack of exercise, and excessive alcohol consumption similarly interact with multiple diseases, amplifying their impact on health.

Initial Drug Discovery

The discovery of new medicines often begins by identifying potential drug candidates. These can originate from a variety of sources, such as traditional remedies, natural products (e.g., plants, microorganisms), or synthetic compounds developed in a laboratory. Scientists investigate how diseases work at a molecular level and search for molecules that could interfere with disease processes or restore normal body functions. This early stage involves extensive research and screening of many compounds to find a few promising ones that might have therapeutic effects.

Preclinical Testing

Once a potential drug compound is identified, it undergoes preclinical testing. This phase involves two main types of tests: in vitro and in vivo. In vitro tests are conducted in laboratories using cells, tissues, or organs isolated from living organisms. These tests help to understand the drug's basic mechanisms of action and initial toxicity. If successful, the drug moves to in vivo tests, which are carried out on live animals. Animal testing aims to evaluate the drug's efficacy (how well it works), its toxicity (any harmful effects), appropriate dosage, and how it is metabolised and excreted by a living system. This step is critical but controversial. Animal testing must be approved and regulated, following strict ethical guidelines to minimise harm.

Clinical Trials (Testing on Humans)

If preclinical results are promising and ethical approval is granted, the drug progresses to clinical trials involving human volunteers. This phase is divided into three main stages:

• Phase 1: Involves a small group of healthy volunteers (typically 20-100 people) to assess the drug's safety, determine a safe dosage range, and study its pharmacology (how it is absorbed, distributed, metabolised, and excreted by the human body).
• Phase 2: Involves a larger group of patients (typically 100-300 people) who have the condition the drug is intended to treat. The primary goal is to evaluate the drug's effectiveness and continue monitoring for side effects.
• Phase 3: Involves a much larger group of patients (hundreds or thousands) and often includes comparisons to existing treatments or a placebo. This phase confirms the drug's efficacy, monitors long-term side effects, and gathers data on common interactions and diverse patient populations. Successful completion of Phase 3 is typically required for regulatory approval.

Approval and Post-Market Monitoring

After successful completion of all clinical trial phases, drug manufacturers submit extensive data to regulatory authorities (e.g., the Medicines and Healthcare products Regulatory Agency in the UK) for review. These authorities meticulously assess all the evidence to ensure the drug is safe, effective, and of high quality before granting marketing approval. Even after a drug is approved and made available to the public, it undergoes continuous post-market surveillance. This involves monitoring for any rare or long-term side effects that may not have been detected during trials, ensuring the ongoing safety of the medicine for wider use. Doctors, pharmacists, and patients are encouraged to report any adverse reactions.

Benefits of Gene Technology in Agriculture

Gene technology offers several advantages for agricultural practices. It can lead to increased crop yields by developing plants resistant to pests and diseases, reducing crop losses. For example, GM crops can be engineered to produce their own insecticides, thereby lowering the need for chemical sprays. This technology also allows for the development of crops that are more tolerant to environmental stresses like drought, salinity, or extreme temperatures, enabling cultivation in challenging conditions. Additionally, gene technology can enhance the nutritional value of food, such as 'Golden Rice' fortified with vitamin A, addressing dietary deficiencies in certain populations. It can also improve the quality and shelf-life of produce, reducing food waste.

Risks and Concerns of Gene Technology in Agriculture

Despite the benefits, gene technology in agriculture raises several concerns. One ecological risk is the potential for outcrossing, where engineered genes spread to wild plant populations or non-GM crops through pollen, potentially creating herbicide-resistant 'superweeds' or impacting biodiversity. There are ongoing debates about the long-term environmental effects, including impacts on beneficial insects or soil microorganisms. Human health concerns, though largely unsubstantiated by scientific consensus for approved GM foods, include fears of allergic reactions or the transfer of antibiotic resistance markers. Economic issues arise from the patenting of GM seeds, which can increase costs for farmers and lead to corporate control of the food supply. Ethical considerations regarding the modification of natural organisms and consumer choice also contribute to public apprehension.